Appendix 4C - Quarterly Report & Brief Company Update
Filed with ASX · · 9 pages · English
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Monepantel reformulation project continues to progress
- New patent secured in US for non-cancer applications
- Reformulation project achieves first milestones and on-track
- PharmAust secures core Europe patent
- PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
Later from Neurizon Therapeutics
- Epichem Update - progress on milestones and revenue targets
- New drugs patented for cancer in USA
- New MPL analogues show greater anti-cancer activity
- PharmAust Raises $1.873m via an Oversubscribed Placement
- Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics